Lil­ly’s Pre­vail taps Jen­nifer Doud­na's spin­out Scribe Ther­a­peu­tics for neu­ro ge­net­ic med­i­cines

Scribe Ther­a­peu­tics found an­oth­er part­ner, this time with Pre­vail Ther­a­peu­tics, a sub­sidiary of Eli Lil­ly, in a $75 mil­lion up­front deal for neu­ro­mus­cu­lar and neu­ro­log­i­cal dis­eases.

Un­like Scribe’s ex vi­vo NK cell ther­a­py part­ner­ship with Sanofi that was an­nounced last fall, the Pre­vail pact is on ex­clu­sive terms for Scribe’s in vi­vo “CRISPR by De­sign” tech­nol­o­gy. Scribe al­so has a col­lab­o­ra­tion with Bio­gen on gene ther­a­py for ALS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER